Craig Sauter, MD

Craig Sauter, MD, a hematologic oncologist and clinical director of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, discusses the differences between off-the-shelf and autologous chimeric antigen receptor (CAR) T-cell products in patients with hematologic malignancies.

The primary advantage of off-the-shelf CAR T-cell therapy is that patients have the opportunity to access cellular therapy in real time, as compared with autologous products that need to be manufactured in the lab, Sauter says.

Having more immediate access to these products is especially important for patients with poor-risk, relapsed/refractory lymphoma. For these patients, time is a critical component of their care; this is especially true for patients who aren’t responding to therapy, which is the current indication for CAR-modified T cells, Sauter adds.

However, there is a possibility that the off-the-shelf CAR T-cell therapy products can be rejected by the host immune system. Approaches to circumnavigate that risk are currently at the forefront of investigation, Sauter concludes.

Videos

Craig Sauter, MD, discusses the differences between off-the-shelf and autologous chimeric antigen receptor T-cell products in patients with hematologic malignancies.

Dr. Sauter on Off-The-Shelf Versus Autologous CAR T-Cell Products in Hematologic Malignancies

Craig Sauter, MD, a hematologic oncologist and clinical director of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, discusses the anecdotal observational data in real-world patients with hematologic malignancies who received chimeric antigen receptor (CAR) T-cell therapy.

Patients are often faced with side effects such as severe cytopenia for long periods of time, says Sauter. If patients fail CAR T-cell therapy, further therapy becomes challenging. When patients progress, they must receive cytotoxic therapy with adequate hematopoietic reserve to tolerate the CAR T cells.

Craig Sauter, MD, discusses the anecdotal observational data in real-world patients with hematologic malignancies who received chimeric antigen receptor T-cell therapy.

Craig Sauter, MD

Articles

Dr. Sauter on Off-The-Shelf Versus Autologous CAR T-Cell Products in Hematologic Malignancies

Dr. Sauter on CAR T Cells in Real-World Patients With Hematologic Malignancies